These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35067035)

  • 21. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
    Kim SA; Kim JW; Suh KJ; Chang W; Kim JW; Oh HK; Cho JY; Kim DW; Cho S; Kim JH; Kim K; Kang SB; Jheon S; Lee KW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2399-2410. PubMed ID: 32358699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
    Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
    Masi G; Cupini S; Marcucci L; Cerri E; Loupakis F; Allegrini G; Brunetti IM; Pfanner E; Viti M; Goletti O; Filipponi F; Falcone A
    Ann Surg Oncol; 2006 Jan; 13(1):58-65. PubMed ID: 16372158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
    Kataoka K; Kanazawa A; Iwamoto S; Kato T; Nakajima A; Arimoto A
    World J Surg; 2014 Apr; 38(4):936-46. PubMed ID: 24166026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
    Nuzzo G; Giuliante F; Ardito F; Vellone M; Pozzo C; Cassano A; Giovannini I; Barone C
    J Gastrointest Surg; 2007 Mar; 11(3):318-24. PubMed ID: 17458605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
    Mima K; Beppu T; Chikamoto A; Miyamoto Y; Nakagawa S; Kuroki H; Okabe H; Hayashi H; Sakamoto Y; Watanabe M; Kikuchi K; Baba H
    Int J Clin Oncol; 2013 Oct; 18(5):847-55. PubMed ID: 22940848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
    Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E;
    ESMO Open; 2020 Nov; 5(6):e000944. PubMed ID: 33148620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion therapy in patients with colorectal liver metastases.
    Villard C; Habib M; Nordenvall C; Nilsson PJ; Jorns C; Sparrelid E
    Eur J Surg Oncol; 2021 Aug; 47(8):2038-2045. PubMed ID: 33640172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    Ychou M; Rivoire M; Thezenas S; Guimbaud R; Ghiringhelli F; Mercier-Blas A; Mineur L; Francois E; Khemissa F; Chauvenet M; Kianmanesh R; Fonck M; Houyau P; Aparicio T; Galais MP; Audemar F; Assenat E; Lopez-Crapez E; Jouffroy C; Adenis A; Adam R; Bouché O
    Br J Cancer; 2022 May; 126(9):1264-1270. PubMed ID: 34992255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
    Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.